Abstract

Pulmonary hypertension (PH) is a rare disorder associated with abnormally elevated pulmonary pressures that, if untreated, leads to right heart failure and premature death. Special population include patents with pulmonary arterial hypertension (PAH). A greater understanding of the epidemiology, pathogenesis, and pathophysiology of PAH has led to significant advances over the past few years. Modern drug therapy provides a significant improvement in patient symptomatic status and a slower rate of clinical deterioration. Despite this, PAH remains a chronic disease without a cure. There is a need for the development of novel therapies and therapeutic strategies, as treatment options are neither universally available nor always effective, possibly due to the large number of mediator and signaling pathways with downstream effectors which are implicated in the pathobiology of PH, and which are not fully reversed during PAH therapy. In the following pages, we review novel strategies for treatment of PAH. For this purpose we summarized the role of specific drug therapies that involve: endothelin receptor antagonists (ERA), phosphodiesterase type 5 inhibitors (PDE-5i) and prostacyclin and prostanoids (PGI2). We focused on novel molecular mechanisms in PAH of recently approved: Guanylate cyclase stimulator and non-prostanoid IP receptor agonist. We discussed novel approach to combined therapy, as well as a new generation of investigational drugs and promising PAH-associated signaling pathways, such as, PDGF, RhoA/ROCK RAAS, HT-5 and others.

References

• 1. Arnold W.P., Mittal C.K., Katsuki S., Murad F.: Nitric oxide activatesguanylate cyclase and increases guanosine 3’:5’-cyclic monophosphatelevels in various tissue preparations. Proc. Natl. Acad.Sci. USA, 1977; 74: 3203-3207
  Google Scholar
• 2. Badesch D.B., Feldman J., Keogh A., Mathier M.A., Oudiz R.J.,Shapiro S., Farber H.W., McGoon M., Frost A., Allard M., Despain D.,Dufton C., Rubin L.J., ARIES-3 Study Group.: ARIES-3: ambrisentantherapy in a diverse population of patients with pulmonary hypertension.Cardiovasc. Ther., 2012; 30: 93-99
  Google Scholar
• 3. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., BadeschD.B., Groves B.M., Tapson V.F., Bourge R.C., Brundage B.H., KoernerS.K., Langleben D., Keller C.A., Murali S., Uretsky B.F. i wsp.: A comparisonof continuous intravenous epoprostenol (prostacyclin) withconventional therapy for primary pulmonary hypertension. N. Engl.J. Med., 1996; 334: 296-301
  Google Scholar
• 4. Bogaard H.J., Natarajan R., Mizuno S., Abbate A., Chang P.J., ChauV.Q., Hoke N.N., Kraskauskas D., Kasper M., Salloum F.N., Voelkel N.F.:Adrenergic receptor blockade reverses right heart remodeling anddysfunction in pulmonary hypertensive rats. Am. J. Respir. Crit. CareMed., 2010; 182: 652-660
  Google Scholar
• 5. Bonnet S., Michelakis E.D., Porter C.J., Andrade-Navarro M.A.,Thébaud B., Bonnet S., Haromy A., Harry G., Moudgil R., McMurtryM.S., Weir E.K., Archer S.L.: An abnormal mitochondrial-hypoxiainducible factor-1α-Kv channel pathway disrupts oxygen sensingand triggers pulmonary arterial hypertension in fawn hooded rats:similarities to human pulmonary arterial hypertension. Circulation,2006; 113: 2630-2641
  Google Scholar
• 6. Cooper C.J., Landzberg M.J., Anderson T.J., Charbonneau F., CreagerM.A., Ganz P., Selwyn A.P.: Role of nitric oxide in the local regulationof pulmonary vascular resistance in humans. Circulation,1996; 93: 266-271
  Google Scholar
• 7. de Man F.S., Tu L., Handoko M.L., Rain S., Ruiter G., François C.,Schalij I., Dorfmüller P., Simonneau G., Fadel E., Perros F., BoonstraA., Postmus P.E., van der Velden J., Vonk-Noordegraaf A. i wsp.:Dysregulated renin-angiotensin-aldosterone system contributesto pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.,2012; 186: 780-789
  Google Scholar
• 8. Dempsie Y., MacLean M.R.: Pulmonary hypertension: therapeutictargets within the serotonin system. Br. J. Pharmacol., 2008; 155:455-462
  Google Scholar
• 9. Do e Z., Fukumoto Y., Takaki A., Tawara S., Ohashi J., Nakano M.,Tada T., Saji K., Sugimura K., Fujita H., Hoshikawa Y., Nawata J., KondoT., Shimokawa H.: Evidence for Rho-kinase activation in patientswith pulmonary arterial hypertension. Circ. J., 2009; 73: 1731-1739
  Google Scholar
• 10. Dumitrascu R., Kulcke C., Königshoff M., Kouri F., Yang X., MorrellN., Ghofrani H.A., Weissmann N., Reiter R., Seeger W., GrimmingerF., Eickelberg O., Schermuly R.T., Pullamsetti S.S.: Tergurideameliorates monocrotaline-induced pulmonary hypertension inrats. Eur. Respir. J., 2011; 37: 1104-1118
  Google Scholar
• 11. Duong-Quy S., Bei Y., Liu Z., Dinh-Xuan A.T.: Role of Rho-kinaseand its inhibitors in pulmonary hypertension. Pharmacol. Ther.,2013; 137: 352-364
  Google Scholar
• 12. Egermayer P., Town G.I., Peacock A.J.: Role of serotonin in thepathogenesis of acute and chronic pulmonary hypertension. Thorax,1999; 54: 161-168
  Google Scholar
• 13. Fedorowicz A., Chłopicki S.: Farmakologia śródbłonka w nadci-śnieniu płucnym. Kardiol. Pol., 2005; 63 (Suppl. 2): S462-S467
  Google Scholar
• 14. Forfia P.R., Mathai S.C., Fisher M.R., Housten-Harris T., HemnesA.R., Champion H.C., Girgis R.E., Hassoun P.M.: Hyponatremia predictsright heart failure and poor survival in pulmonary arterialhypertension. Am. J. Respir. Crit. Care Med., 2008; 177: 1364-1369
  Google Scholar
• 15. Francis S.H., Busch J.L., Corbin J.D., Sibley D.: cGMP-dependentprotein kinases and cGMP phosphodiesterases in nitric oxide andcGMP action. Pharmacol. Rev., 2010; 62: 525-563
  Google Scholar
• 16. Frantz R.P., McDevitt S., Walker S.: Baseline NT-proBNP correlateswith change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil studyTRIUMPH-1. J. Heart Lung Transplant., 2012; 31: 811-816
  Google Scholar
• 17. Frishman W.H., Huberfeld S., Okin S., Wang Y.H., Kumar A., ShareefB.: Serotonin and serotonin antagonism in cardiovascular andnon-cardiovascular disease. J. Clin. Pharmacol., 1995; 35: 541-572
  Google Scholar
• 18. Fukumoto Y., Matoba T., Ito A., Tanaka H., Kishi T., HayashidaniS., Abe K., Takeshita A., Shimokawa H.: Acute vasodilator effects ofa Rho-kinase inhibitor, fasudil, in patients with severe pulmonaryhypertension. Heart, 2005; 91: 391-392
  Google Scholar
• 19. Fukumoto Y., Yamada N., Matsubara H., Mizoguchi M., UchinoK., Yao A., Kihara Y., Kawano M., Watanabe H., Takeda Y., Adachi T.,Osanai S., Tanabe N., Inoue T., Kubo A. i wsp.: Double-blind, placebocontrolledclinical trial with a rho-kinase inhibitor in pulmonaryarterial hypertension. Circ. J., 2013; 77: 2619-2625
  Google Scholar
• 20. Galie N., Barbera J.A., Frost A.E., Ghofrani H.A., Hoeper M.M., McLaughlin V.V., Peacock A.J., Simonneau G., Vachiery J.L., Grünig E.,Oudiz R.G., Vonk-Nordegraaf A., White R.J., Blair C., Gillies H. i wsp.:Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.N. Engl. J. Med., 2015; 373: 834–844
  Google Scholar
• 21. Galie N., Boonstra A., Ewert R., Gomez-Sanchez M.A., BarberaJ.A., Torbicki A., Bremer H., Ghofrani A., Naeije R., Gruenig E., LeuchteH., Simonneau G., Klose H., Peacock A., Wilkens H. i wsp.: Effects ofinhaled aviptadil (vasoactive intestinal peptide) in patients withpulmonary arterial hypertension (PAH). Am. J. Respir. Crit. CareMed., 2010; 181: A2516
  Google Scholar
• 22. Galiè N., Corris P.A., Frost A., Girgis R.E., Granton J., Jing Z.C.,Klepetko W., McGoon M.D., McLaughlin V.V., Preston I.R., Rubin L.J.,Sandoval J., Seeger W., Keogh A.: Updated treatment algorithm ofpulmonary arterial hypertension. J. Am. Coll. Cardiol., 2013; 62 (Suppl.25): D60-D72
  Google Scholar
• 23. Galiè N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L.,Barbera J.A., Beghetti M., Corris P., Gaine S., Gibbs J.S., Gomez-SanchezM.A., Jondeau G., Klepetko W., Opitz C., Peacock A. i wsp.: Guidelinesfor the diagnosis and treatment of pulmonary hypertension.Eur. Respir. J., 2009; 34: 1219-1263
  Google Scholar
• 24. Galié N., Manes A., Branzi A.: The endothelin system in pulmonaryarterial hypertension. Cardiovasc. Res., 2004; 61: 227-237
  Google Scholar
• 25. Galiè N., Müller K., Scalise A.V., Grünig E.: PATENT PLUS: a blinded,randomised and extension study of riociguat plus sildenafil inpulmonary arterial hypertension. Eur. Respir. J., 2015; 45: 1314-1322
  Google Scholar
• 26. Galiè N., Palazzini M., Manes A.: Pulmonary arterial hypertension:from the kingdom of the near-dead to multiple clinical trialmeta-analyses. Eur. Heart J., 2010; 31: 2080-2086
  Google Scholar
• 27. Ghofrani H.A., Galiè N., Grimminger F., Grünig E., Humbert M.,Jing Z.C., Keogh A.M., Langleben D., Kilama M.O., Fritsch A., NeuserD., Rubin L.J.; PATENT-1 Study Group: Riociguat for the treatment ofpulmonary arterial hypertension. N. Engl. J. Med., 2013; 369: 330-340
  Google Scholar
• 28. Ghofrani H.A., Morrell N.W., Hoeper M.M., Olschewski H., PeacockA.J., Barst R.J., Shapiro S., Golpon H., Toshner M., GrimmingerF., Pascoe S.: Imatinib in pulmonary arterial hypertension patientswith inadequate response to established therapy. Am. J. Respir. Crit.Care Med., 2010; 182: 1171-1177
  Google Scholar
• 29. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., ShennibH., Kimura S., Masaki T., Duguid W.P., Stewart D.J.: Expression ofendothelin-1 in the lungs of patients with pulmonary hypertension.N. Engl. J. Med., 1993; 328: 1732-1739
  Google Scholar
• 30. Gomberg-Maitland M., Bull T.M., Saggar R., Barst R.J., ElgazayerlyA., Fleming T.R., Grimminger F., Rainisio M., Stewart D.J., StockbridgeN., Ventura C., Ghofrani A.H., Rubin L.J.: New trial designs andpotential therapies for pulmonary artery hypertension. J. Am. Coll.Cardiol., 2013; 62 (Suppl. 25): D82-D91
  Google Scholar
• 31. Guilluy C., Eddahibi S., Agard C., Guignabert C., Izikki M., Tu L.,Savale L., Humbert M., Fadel E., Adnot S., Loirand G., Pacaud P.: RhoAand Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am. J. Respir. Crit. Care Med., 2009; 179: 1151-1158
  Google Scholar
• 32. Gunaydin S., Imai Y., Takanashi Y., Seo K., Hagino I., Chang D.,Shinoka T.: The effects of vasoactive intestinal peptide on monocrotalineinduced pulmonary hypertensive rabbits following cardiopulmonarybypass: a comparative study with isoproteronol andnitroglycerine. Cardiovasc. Surg., 2002; 10: 138-145
  Google Scholar
• 33. Heldin C.H., Westermark B.: Mechanism of action and in vivo roleof platelet-derived growth factor. Physiol. Rev., 1999; 79: 1283-1316
  Google Scholar
• 34. Hoeper M.M., Barst R.J., Bourge R.C., Feldman J., Frost A.E.,Galié N., Gómez-Sánchez M.A., Grimminger F., Grünig E., HassounP.M., Morrell N.W., Peacock A.J., Satoh T., Simonneau G., Tapson V.F.i wsp.: Imatinib mesylate as add-on therapy for pulmonary arterialhypertension: results of the randomized IMPRES study. Circulation,2013; 127: 1128-1138
  Google Scholar
• 35. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galiè N.,Boonstra A., Rubin L.J., Horn E.M., Manes A., Simonneau G.: Combinationof bosentan with epoprostenol in pulmonary arterial hypertension:BREATHE-2. Eur. Respir. J., 2004; 24: 353-359
  Google Scholar
• 36. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLeanM.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., VoelkelN.F., Rabinovitch M.: Cellular and molecular pathobiology of pulmonaryarterial hypertension. J. Am. Coll. Cardiol., 2004; 43 (Suppl.12S): 13S-24S
  Google Scholar
• 37. Ishikura K., Yamada N., Ito M., Ota S., Nakamura M., Isaka N.,Nakano T.: Beneficial acute effects of rho-kinase inhibitor in patientswith pulmonary arterial hypertension. Circ. J., 2006; 70: 174-178
  Google Scholar
• 38. Janssen W., Schymura Y., Novoyatleva T., Kojonazarov B., BoehmM., Wietelmann A., Luitel H., Murmann K., Krompiec D.R., Tretyn A.,Pullamsetti S.S., Weissmann N., Seeger W., Ghofrani H.A., SchermulyR.T.: 5-HT2B receptor antagonists inhibit fibrosis and protect fromRV heart failure. Biomed. Res. Int., 2015; 2015: 438403
  Google Scholar
• 39. Jasińska-Stroschein M., Orszulak-Michalak D.: The current approachinto signaling pathways in pulmonary arterial hypertensionand their implication in novel therapeutic strategies. Pharmacol.Rep., 2014; 66: 552-564
  Google Scholar
• 40. Jasińska-Stroschein M., Owczarek J., Plichta P., Orszulak-MichalakD.: Concurrent rho-kinase and tyrosine kinase platelet-derivedgrowth factor inhibition in experimental pulmonary hypertension.Pharmacology, 2014; 93: 145-150
  Google Scholar
• 41. Jing Z.C., Yu Z.X., Shen J.Y., Wu B.X., Xu K.F., Zhu X.Y., Pan L.,Zhang Z.L., Liu X.Q., Zhang Y.S., Jiang X., Galiè N.; Efficacy and safetyof vardenafil in the treatment of pulmonary arterial hypertension(EVALUATION) study group: Vardenafil in pulmonary arterial hypertension:a randomized, double-blind, placebo-controlled study.Am. J. Respir. Crit. Care Med., 2011; 183: 1723-1729
  Google Scholar
• 42. Katsiki N., Wierzbicki A.S., Mikhailidis D.P.: Pulmonary arterialhypertension and statins: an update. Curr. Opin. Cardiol., 2011;26: 322-326
  Google Scholar
• 43. Kawut S.M., Horn E.M., Berekashvili K.K., Lederer D.J., WidlitzA.C., Rosenzweig E.B., Barst R.J.: Selective serotonin reuptake inhibitoruse and outcomes in pulmonary arterial hypertension. Pulm.Pharmacol. Ther., 2006; 19: 370-374
  Google Scholar
• 44. Klein M., Schermuly R.T., Ellinghaus P., Milting H., Riedl B., NikolovaS., Pullamsetti S.S., Weissmann N., Dony E., Savai R., GhofraniH.A., Grimminger F., Busch A.E., Schäfer S.: Combined tyrosine andserine/threonine kinase inhibition by sorafenib prevents progressionof experimental pulmonary hypertension and myocardial remodeling.Circulation, 2008; 118: 2081-2090
  Google Scholar
• 45. Kloza M., Baranowska-Kuczko M., Pędzińska-Betiuk A., JackowskiK., Kozłowska H.: Teoria serotoninowa a tętnicze nadciśnieniepłucne. Postępy Hig. Med. Dośw., 2014; 68: 738-748
  Google Scholar
• 46. Kurzyna M.: Epidemiologia i leczenie nadciśnienia płucnegow Polsce AD 2015. http://www.ptkardio.pl/Epidemiologia_i_leczenie_nadcisnienia_plucnego_w_Polsce_AD_2015-2485(05.05.2016)
  Google Scholar
• 47. Lajoie A.C., Lauzière G., Lega J.C., Lacasse Y., Martin S., Simard S.,Bonnet S., Provencher S.: Combination therapy versus monotherapyfor pulmonary arterial hypertension: a meta-analysis. Lancet Respir.Med., 2016; 4: 291-305
  Google Scholar
• 48. Laufs U., Marra D., Node K., Liao J.K.: 3-Hydroxy-3-methylglutaryl-CoAreductase inhibitors attenuate vascular smooth muscleproliferation by preventing rho GTPase-induced down-regulationof p27(Kip1). J. Biol. Chem., 1999; 274: 21926-21931
  Google Scholar
• 49. Leuchte H.H., Baezner C., Baumgartner R.A., Bevec D., BacherG., Neurohr C., Behr J.: Inhalation of vasoactive intestinal peptide inpulmonary hypertension. Eur. Respir. J., 2008; 32: 1289-1294
  Google Scholar
• 50. Liao J.K., Laufs U.: Pleiotropic effects of statins. Annu. Rev. Pharmacol.Toxicol., 2005; 45: 89-118
  Google Scholar
• 51. Maruno K., Absood A., Said S.I.: VIP inhibits basal and histaminestimulatedproliferation of human airway smooth muscle cells. Am.J. Physiol., 1995; 268: L1047-L1051
  Google Scholar
• 52. McLaughlin V., Channick R.N., Ghofrani H.A., Lemarié J.C., NaeijeR., Packer M., Souza R., Tapson V.F., Tolson J., Al Hiti H., Meyer G.,Hoeper M.M.: Bosentan added to sildenafil therapy in patients withpulmonary arterial hypertension. Eur. Respir. J., 2015; 46: 405-413
  Google Scholar
• 53. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S.,Channick R.N., Badesch D.B., Barst R.J., Hsu H.H., Rubin L.J.: Randomizedstudy of adding inhaled iloprost to existing bosentan inpulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.,2006; 174: 1257-1263
  Google Scholar
• 54. Moreno-Vinasco L., Garcia J.G.: Receptor tyrosine kinase inhibitorsin rodent pulmonary hypertension. Adv. Exp. Med. Biol.,2010; 661: 419-434
  Google Scholar
• 55. Morrell N.W., Adnot S., Archer S.L., Dupuis J., Jones P.L., MacLeanM.R., McMurtry I.F., Stenmark K.R., Thistlethwaite P.A., WeissmannN., Yuan J.X., Weir E.K.: Cellular and molecular basis of pulmonary arterialhypertension. J. Am. Coll. Cardiol., 2009; 54 (Suppl. 1): S20-S31
  Google Scholar
• 56. Mubarak K.K.: A review of prostaglandin analogs in the managementof patients with pulmonary arterial hypertension. Respir.Med., 2010; 104: 9-21
  Google Scholar
• 57. Patterson K.C., Weissmann A., Ahmadi T., Farber H.W.: Imatinibmesylate in the treatment of refractory idiopathic pulmonary arterialhypertension. Ann. Intern. Med., 2006; 145: 152-153
  Google Scholar
• 58. Perros F., Montani D., Dorfmüller P., Durand-Gasselin I., TcherakianC., Le Pavec J., Mazmanian M., Fadel E., Mussot S., MercierO., Hervé P., Emilie D., Eddahibi S., Simonneau G., Souza R. i wsp.:Platelet-derived growth factor expression and function in idiopathicpulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.,2008; 178: 81-88
  Google Scholar
• 59. Petkov V., Mosgoeller W., Ziesche R., Raderer M., StiebellehnerL., Vonbank K., Funk G.C., Hamilton G., Novotny C., Burian B., BlockL.H.: Vasoactive intestinal peptide as a new drug for treatment of primarypulmonary hypertension. J. Clin. Invest., 2003; 111: 1339-1346
  Google Scholar
• 60. Provencher S., Herve P., Jais X., Lebrec D., Humbert M., SimonneauG., Sitbon O.: Deleterious effects of β-blockers on exercise capacityand hemodynamics in patients with portopulmonary hypertension.Gastroenterology, 2006; 130: 120-126
  Google Scholar
• 61. Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galiè N.,Ghofrani H.A., Jansa P., Jing Z.C., Le Brun F.O., Mehta S., MittelholzerC.M., Perchenet L., Sastry B.K., Sitbon O., Souza R. i wsp.: Macitentanand morbidity and mortality in pulmonary arterial hypertension.N. Engl. J. Med., 2013; 369: 809-818
  Google Scholar
• 62. Rossaint R., Pison U., Gerlach H., Falke K.J.: Inhaled nitric oxide:its effects on pulmonary circulation and airway smooth muscle cells.Eur. Heart J., 1993; 14 (Suppl. I): 133-140
  Google Scholar
• 63. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R.,Roth M., Sydykov A., Lai Y.J., Weissmann N., Seeger W., GrimmingerF.: Reversal of experimental pulmonary hypertension by PDGF inhibition.J. Clin. Invest., 2005; 115: 2811-2821
  Google Scholar
• 64. Simonneau G., Gatzoulis M.A., Adatia I., Celermajer D., DentonC., Ghofrani A., Gomez Sanchez M.A., Krishna Kumar R., LandzbergM., Machado R.F., Olschewski H., Robbins I.M., Souza R.: Updatedclinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.,2013; 62: D34-D41
  Google Scholar
• 65. Simonneau G., Rubin L., Galie` N., Barst R.J., Fleming T.R., FrostA.E., Engel P.J., Kramer M.R., Burgess G., Collings L., Cossons N., SitbonO., Badesch B.D.: Addition of sildenafil to long-term intravenousepoprostenol therapy in patients with pulmonary arterial hypertension:a randomized trial. Ann. Intern. Med., 2008; 149: 521-530
  Google Scholar
• 66. Simonneau G., Rubin L.J., Galiè N., Barst R.J., Fleming T.R., FrostA., Engel P., Kramer M.R., Serdarevic-Pehar M., Layton G.R., SitbonO., Badesch D.B.; PACES Study Group: Long-term sildenafil added tointravenous epoprostenol in patients with pulmonary arterial hypertension.J. Heart Lung Transplant., 2014; 33: 689-697
  Google Scholar
• 67. Sitbon O., Channick R., Chin K.M., Frey A., Gaine S., Galiè N.,Ghofrani H.A., Hoeper M.M., Lang I.M., Preiss R., Rubin L.J., Di ScalaL., Tapson V., Adzerikho I., Liu J. i wsp.: Selexipag for the treatmentof pulmonary arterial hypertension. N. Engl. J. Med., 2015;373: 2522-2533
  Google Scholar
• 68. Sitbon O., Jaıs X., Savale L., Cottin V., Bergot E., Macari E.A., BouvaistH., Dauphin C., Picard F., Bulifon S., Montani D., Humbert M.,Simonneau G.: Upfront triple combination therapy in pulmonaryarterial hypertension: a pilot study. Eur. Respir. J., 2014; 43: 1691-1697
  Google Scholar
• 69. Sutendra G., Bonnet S., Rochefort G., Haromy A., Folmes K.D.,Lopaschuk G.D., Dyck J.R., Michelakis E.D.: Fatty acid oxidation andmalonyl-CoA decarboxylase in the vascular remodeling of pulmonaryhypertension. Sci. Transl. Med., 2010; 2: 44ra58
  Google Scholar
• 70. Taraseviciene-Stewart L., Scerbavicius R., Choe K.H., Cool C.,Wood K., Tuder R.M., Burns N., Kasper M., Voelkel N.F.: Simvastatincauses endothelial cell apoptosis and attenuates severe pulmonaryhypertension. Am. J. Physiol. Lung Cell. Mol. Physiol., 2006; 291:L668-L676
  Google Scholar
• 71. The Joint Task Force for the Diagnosis and Treatment of PulmonaryHypertension of the European Society of Cardiology (ESC) andthe European Respiratory Society (ERS): Endorsed by: Associationfor European Paediatric and Congenital Cardiology (AEPC), InternationalSociety for Heart and Lung Transplantation (ISHLT). Eur.Heart J., 2016; 37: 67-119
  Google Scholar
• 72. Velayati A., Valerio M.G., Shen M., Tariq S., Lanier G.M., AronowW.S.: Update on pulmonary arterial hypertension pharmacotherapy.Postgrad. Med., 2016; 128: 460-473
  Google Scholar
• 73. Waxman A.B., Zamanian R.T.: Pulmonary arterial hypertension:new insights into the optimal role of current and emergingprostacyclin therapies. Am. J. Cardiol., 2013; 111 (Suppl. 5): 1A-16A
  Google Scholar
• 74. Wharton J., Strange J.W., Møller G.M., Growcott E.J., Ren X.,Franklyn A.P., Phillips S.C., Wilkins M.R.: Antiproliferative effectsof phosphodiesterase type 5 inhibition in human pulmonary arterycells. Am. J. Respir. Crit. Care Med., 2005; 172: 105-113
  Google Scholar

Full text